[
  {
    "ts": "2025-10-15T20:08:45+00:00",
    "headline": "Why Moderna Might Be a One-Hit Wonder",
    "summary": "Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.",
    "url": "https://www.fool.com/investing/2025/10/15/why-moderna-might-be-a-one-hit-wonder/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "49a9d4c4-a5da-3324-96bd-6eae4d6f1535",
      "content": {
        "id": "49a9d4c4-a5da-3324-96bd-6eae4d6f1535",
        "contentType": "STORY",
        "title": "Why Moderna Might Be a One-Hit Wonder",
        "description": "",
        "summary": "Moderna's sales have plummeted in recent years along with diminishing demand for COVID vaccines.",
        "pubDate": "2025-10-15T20:08:45Z",
        "displayTime": "2025-10-15T20:08:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/5536f9b125e780cd17b1d0e8c531e519",
          "originalWidth": 1200,
          "originalHeight": 801,
          "caption": "Person with a headache tracking charts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OWZ1oa9UEoe5TknEreZSXA--~B/aD04MDE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5536f9b125e780cd17b1d0e8c531e519.cf.webp",
              "width": 1200,
              "height": 801,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FakUdG3v.FNb.t3AjTZiEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/5536f9b125e780cd17b1d0e8c531e519.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/15/why-moderna-might-be-a-one-hit-wonder/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-moderna-might-one-hit-200845093.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T19:47:19+00:00",
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks increased late Wednesday afternoon with the NYSE Health Care Index and the Health",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-194719156.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "7f4d46ed-3759-35c9-91dc-ac44056e3442",
      "content": {
        "id": "7f4d46ed-3759-35c9-91dc-ac44056e3442",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Advance Late Afternoon",
        "description": "",
        "summary": "Health care stocks increased late Wednesday afternoon with the NYSE Health Care Index and the Health",
        "pubDate": "2025-10-15T19:47:19Z",
        "displayTime": "2025-10-15T19:47:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-194719156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-advance-194719156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "OMER"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T12:40:00+00:00",
    "headline": "Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?",
    "summary": "Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.",
    "url": "https://finance.yahoo.com/news/pharma-m-activity-picks-pace-124000704.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "59192b2f-aac5-3a93-b400-9277fafce937",
      "content": {
        "id": "59192b2f-aac5-3a93-b400-9277fafce937",
        "contentType": "STORY",
        "title": "Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?",
        "description": "",
        "summary": "Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.",
        "pubDate": "2025-10-15T12:40:00Z",
        "displayTime": "2025-10-15T12:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4mGL7zFW4ML.rueGFlAaKQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i_0DPni3TtRoN19G7I0YLA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pharma-m-activity-picks-pace-124000704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pharma-m-activity-picks-pace-124000704.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T11:59:00+00:00",
    "headline": "Cell and Gene Therapy Drug Delivery Research Report 202-2035: Rising Prevalence of Chronic and Genetic Disorders and Demand for Targeted Therapeutic Delivery Solutions Fuel Advances",
    "summary": "The cell and gene therapy drug delivery market plays a pivotal role in advancing precision medicine by ensuring the effective introduction of living cells and genetically modified genes into patients. This specialized delivery process, using tools like pre-filled syringes and infusion pumps, addresses challenges such as cell stability and immune rejection. Driven by rising chronic diseases like cancer and diabetes, demand for these targeted therapies is growing. However, high costs in manufactur",
    "url": "https://finance.yahoo.com/news/cell-gene-therapy-drug-delivery-115900756.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "5cb33c3c-9198-34ea-b9c3-f4b7060e79f6",
      "content": {
        "id": "5cb33c3c-9198-34ea-b9c3-f4b7060e79f6",
        "contentType": "STORY",
        "title": "Cell and Gene Therapy Drug Delivery Research Report 202-2035: Rising Prevalence of Chronic and Genetic Disorders and Demand for Targeted Therapeutic Delivery Solutions Fuel Advances",
        "description": "",
        "summary": "The cell and gene therapy drug delivery market plays a pivotal role in advancing precision medicine by ensuring the effective introduction of living cells and genetically modified genes into patients. This specialized delivery process, using tools like pre-filled syringes and infusion pumps, addresses challenges such as cell stability and immune rejection. Driven by rising chronic diseases like cancer and diabetes, demand for these targeted therapies is growing. However, high costs in manufactur",
        "pubDate": "2025-10-15T11:59:00Z",
        "displayTime": "2025-10-15T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cell-gene-therapy-drug-delivery-115900756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cell-gene-therapy-drug-delivery-115900756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T11:53:14+00:00",
    "headline": "Market Chatter: Pfizer CEO Reportedly Says US Pharmaceutical Industry Should Collaborate With Chinese Counterparts",
    "summary": "Pfizer (PFE) Chief Executive Albert Bourla said the US pharmaceutical industry needs to collaborate",
    "url": "https://finance.yahoo.com/news/market-chatter-pfizer-ceo-reportedly-115314949.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "05f6c833-9cda-34ca-ae93-f76983796c33",
      "content": {
        "id": "05f6c833-9cda-34ca-ae93-f76983796c33",
        "contentType": "STORY",
        "title": "Market Chatter: Pfizer CEO Reportedly Says US Pharmaceutical Industry Should Collaborate With Chinese Counterparts",
        "description": "",
        "summary": "Pfizer (PFE) Chief Executive Albert Bourla said the US pharmaceutical industry needs to collaborate",
        "pubDate": "2025-10-15T11:53:14Z",
        "displayTime": "2025-10-15T11:53:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-pfizer-ceo-reportedly-115314949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/market-chatter-pfizer-ceo-reportedly-115314949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T11:40:43+00:00",
    "headline": "Pfizer touts Tukysa in front-line breast cancer after Phase III victory",
    "summary": "If approved alongside current SoC maintenance therapies, Tukysa could become the first update to the regimen for HER2-positive breast cancer in over a decade.",
    "url": "https://www.pharmaceutical-technology.com/news/pfizer-tukysa-phase-iii-her2-breast-cancer-maintenance-trial/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "63444d77-55ba-3e9e-978e-f96bd77db046",
      "content": {
        "id": "63444d77-55ba-3e9e-978e-f96bd77db046",
        "contentType": "STORY",
        "title": "Pfizer touts Tukysa in front-line breast cancer after Phase III victory",
        "description": "",
        "summary": "If approved alongside current SoC maintenance therapies, Tukysa could become the first update to the regimen for HER2-positive breast cancer in over a decade.",
        "pubDate": "2025-10-15T11:40:43Z",
        "displayTime": "2025-10-15T11:40:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/af1933d7600752235e961c9f2485349f",
          "originalWidth": 2560,
          "originalHeight": 1408,
          "caption": "Pfizer's TKI",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EaPBUsofRV70485XFpP4Gw--~B/aD0xNDA4O3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/pharmaceutical_technology_376/af1933d7600752235e961c9f2485349f.cf.webp",
              "width": 2560,
              "height": 1408,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mUfMociOapihpKzg17Qx3g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/af1933d7600752235e961c9f2485349f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/pfizer-tukysa-phase-iii-her2-breast-cancer-maintenance-trial/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-touts-tukysa-front-line-114043464.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T11:34:00+00:00",
    "headline": "Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships",
    "summary": "The market for VZV infection treatment is driven by increased vaccination and antiviral use, rising elderly populations, and strong immunization programs in developed regions. Key opportunities include expanding vaccine access in developing countries, R&D in new vaccine technologies, and managing competition from generics.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Varicella Zoster Virus Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key",
    "url": "https://finance.yahoo.com/news/varicella-zoster-virus-infection-treatment-113400016.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "8ee02cff-f9dc-37d3-8552-b46a15baf376",
      "content": {
        "id": "8ee02cff-f9dc-37d3-8552-b46a15baf376",
        "contentType": "STORY",
        "title": "Varicella Zoster Virus Infection Treatment Research Report 2025: Market Dominated by Merck, GSK, Pfizer, and Novartis by Utilizing Regional Biotech Expansion and Global Immunization Partnerships",
        "description": "",
        "summary": "The market for VZV infection treatment is driven by increased vaccination and antiviral use, rising elderly populations, and strong immunization programs in developed regions. Key opportunities include expanding vaccine access in developing countries, R&D in new vaccine technologies, and managing competition from generics.Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The \"Varicella Zoster Virus Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key",
        "pubDate": "2025-10-15T11:34:00Z",
        "displayTime": "2025-10-15T11:34:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/varicella-zoster-virus-infection-treatment-113400016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/varicella-zoster-virus-infection-treatment-113400016.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVN.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T11:00:00+00:00",
    "headline": "ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir",
    "summary": "LONDON, October 15, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase I CLARITY open-label, crossover study, showing clinically relevant differences in injection site reaction (ISR) acceptability and tolerability, with 69% of HIV-negative adults finding cabotegravir long-acting (CAB LA) injections to be \"totally or very acceptable\" vs 48% for lenacapavir (LEN) injections. Data presented at",
    "url": "https://finance.yahoo.com/news/viiv-healthcare-clarity-study-shows-110000200.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "42c6cc36-baf1-3391-9be9-8b9cbf751e91",
      "content": {
        "id": "42c6cc36-baf1-3391-9be9-8b9cbf751e91",
        "contentType": "STORY",
        "title": "ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir",
        "description": "",
        "summary": "LONDON, October 15, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced data from the phase I CLARITY open-label, crossover study, showing clinically relevant differences in injection site reaction (ISR) acceptability and tolerability, with 69% of HIV-negative adults finding cabotegravir long-acting (CAB LA) injections to be \"totally or very acceptable\" vs 48% for lenacapavir (LEN) injections. Data presented at",
        "pubDate": "2025-10-15T11:00:00Z",
        "displayTime": "2025-10-15T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c8e5c012467dbb0c98cf0bcc33dd3e22",
          "originalWidth": 320,
          "originalHeight": 296,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LgqoEA4JFb58EkYlHCRSqg--~B/aD0yOTY7dz0zMjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c8e5c012467dbb0c98cf0bcc33dd3e22.cf.webp",
              "width": 320,
              "height": 296,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ij9Fh8djTCql0igV0nWkzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c8e5c012467dbb0c98cf0bcc33dd3e22.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viiv-healthcare-clarity-study-shows-110000200.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viiv-healthcare-clarity-study-shows-110000200.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4507.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T10:19:00+00:00",
    "headline": "Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics",
    "summary": "Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.",
    "url": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-akebia-101900485.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "61098050-0bd3-3ee4-977b-66cb75a972a1",
      "content": {
        "id": "61098050-0bd3-3ee4-977b-66cb75a972a1",
        "contentType": "STORY",
        "title": "Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics",
        "description": "",
        "summary": "Small-cap biotech momentum surges as AKBA, IRWD, PYXS, CRDL, and PSTV gain on pipeline progress and sector recovery.",
        "pubDate": "2025-10-15T10:19:00Z",
        "displayTime": "2025-10-15T10:19:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xubTnAbsCPnw2obvb7FmXA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lcL5Qr7_.1czomowImosdw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-akebia-101900485.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-akebia-101900485.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AKBA"
            },
            {
              "symbol": "IRWD"
            },
            {
              "symbol": "PYXS"
            },
            {
              "symbol": "CRDL.TO"
            },
            {
              "symbol": "PSTV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-15T04:39:16+00:00",
    "headline": "1 Safe-and-Steady Stock Worth Your Attention and 2 We Question",
    "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
    "url": "https://finance.yahoo.com/news/1-safe-steady-stock-worth-043916167.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "46932eb1-62b7-3c91-964d-9fbfe3b092e3",
      "content": {
        "id": "46932eb1-62b7-3c91-964d-9fbfe3b092e3",
        "contentType": "STORY",
        "title": "1 Safe-and-Steady Stock Worth Your Attention and 2 We Question",
        "description": "",
        "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
        "pubDate": "2025-10-15T04:39:16Z",
        "displayTime": "2025-10-15T04:39:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/24f1ce460a304ef1a440e4edeacad2ba",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "RELY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DzOAYDS2MB7AJbSF9GrXFA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/24f1ce460a304ef1a440e4edeacad2ba.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ySp2Mj5xl2LRAgcQ3qgUkg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/24f1ce460a304ef1a440e4edeacad2ba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-safe-steady-stock-worth-043916167.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-safe-steady-stock-worth-043916167.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALL"
            },
            {
              "symbol": "ALL-PH"
            },
            {
              "symbol": "ALL-PI"
            },
            {
              "symbol": "ALL-PJ"
            },
            {
              "symbol": "RELY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]